Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

Kashiv BioSciences, LLC today announced positive topline results from its confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab).

REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global ...

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk ...

Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the Cε3 domain of IgE and forms complexes that inhibit the immune system's response to allergens by averting IgE- ...

A medication called omalizumab (often sold as Xolair) has been around for a long time and was used to help deal with asthma.

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

The Johns Hopkins-led OUtMATCH study, which enrolled clinical trial participants at 10 locations across the U.S., leads to ...

Joseph spent his childhood dreading family gatherings. His Egyptian-American relatives would gather around the family table ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...